Abstract
To address the growing epidemic of liver disease, particularly in pediatric populations, it is crucial to identify modifiable risk factors for the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Per- and polyfluoroalkyl substances (PFAS) are persistent ubiquitous chemicals and have emerged as potential risk factors for liver damage. However, their impact on the etiology and severity of MASLD remains largely unexplored in humans. This study aims to bridge the gap between human and in vitro studies to understand how exposure to perfluoroheptanoic acid (PFHpA), one of the emerging PFAS replacements which accumulates in high concentrations in the liver, contributes to MASLD risk and progression. First, we showed that PFHpA plasma concentrations were significantly associated with increased risk of MASLD in obese adolescents. Further, we examined the impact of PFHpA on hepatic metabolism using 3D human liver spheroids and single-cell transcriptomics to identify major hepatic pathways affected by PFHpA. Next, we integrated the in vivo and in vitro multi-omics datasets with a novel statistical approach which identified signatures of proteins and metabolites associated with MASLD development triggered by PFHpA exposure. In addition to characterizing the contribution of PFHpA to MASLD progression, our study provides a novel strategy to identify individuals at high risk of PFHpA-induced MASLD and develop early intervention strategies. Notably, our analysis revealed that the proteomic signature exhibited a stronger correlation between both PFHpA exposure and MASLD risk compared to the metabolomic signature. While establishing a clear connection between PFHpA exposure and MASLD progression in humans, our study delved into the molecular mechanisms through which PFHpA disrupts liver metabolism. Our in vitro findings revealed that PFHpA primarily impacts lipid metabolism, leading to a notable increase of lipid accumulation in human hepatocytes after PFHpA exposure. Among the pathways involved in lipid metabolism in hepatocytes, regulation of lipid metabolism by PPAR-a showed a remarkable activation. Moreover, the translational research framework we developed by integrating human and in vitro data provided us biomarkers to identify individuals at a high risk of MASLD due to PFHpA exposure. Our framework can inform policies on PFAS-induced liver disease and identify potential targets for prevention and treatment strategies.
Competing Interest Statement
The authors declare that they have no conflicts of interest apart from Dr. Bartell who has provided paid expert assistance in legal cases involving PFAS exposed populations.
Funding Statement
The results reported herein correspond to specific aims of grant R01ES030691 to Dr.Chatzi from the National Institute of Environmental Health Science (NIEHS). Additional funding from NIEHS supported Dr. Chatzi (R01ES029944 R01ES030364 U01HG013288 and P30ES007048 European Union- The Advancing Tools for Human Early Lifecourse Exposome Research and Translation (ATHLETE) project, grant agreement number 874583) Dr. Baumert (R01ES030691 R01ES030364, and T32ES013678) Dr. Goodrich (P30ES007048 and U01HG013288) Dr. Aung (P30ES007048 and U01HG013288) Dr. Valvi (R01ES033688 R21ES035148 and P30ES023515) Dr. Walker (R01ES030691 U2CES030859 and R01ES032831) Dr. McConnell (P30ES007048 P2C ES033433) and Dr. La Merrill (R01ES030364) Dr. Conti (R21ES029681 R01ES030691, R01ES030364 R01ES029944 P01CA196569 and P30ES007048) Dr. Sisley (R01DK12811701A1). Dr. Stratakis received funding from European Union Horizon Europe research and innovation programme under the Marie Skłodowska-Curie Actions Postdoctoral Fellowships (101059245). Dr. La Merrill was additionally supported by the California Environmental Protection Agency (20E0017). Dr. Sisley was additionally supported by Department of Agriculture (625051000053). The TeenLABS consortium is supported by cooperative agreements with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) through grants for a clinical coordinating center (UM1DK072493 Inge) and the Data Coordinating Center (UM1DK095710).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for this study was provided by the University of Southern California Institutional Review Board (IRB protocols HS1900057). Prior to participation, written informed assent and consent were obtained from participants and their guardians. The Teen -Longitudinal Assessment of Bariatric Surgery (TeenLABS) study (ClinicalTrials.gov number, NCT00474318) was designed as prospective, multicenter, observational study of consecutive cases of bariatric surgery offered to adolescents. The study methodology has been previously described.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw and processed scRNA-seq datasets were deposited into the NCBI GEO database under the accession number GSE253186. All Teen-LABS data and metadata are uploaded, stored and make available through the existing NIH-NIDDK Central Repository.